Clinical Trial: Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI6

Brief Summary: The study aims to confirm long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease. It is a pivotal trial intended to support the registration of LCI699 for the treatment of patients with Cushing's disease in the EU, Japan, and other countries.